 |
 |
Below are excerpts from recent Press Release on a PhRMA survey. Included are numbers to call for follow-up information and/or participation in the study Perry Cohen Washington DC www.parkinsonscare.org http://www.phrma.org/searchcures/newmeds/neurologic2001/ December 17, 2001 PhRMA Survey Finds 176 Medicines in the Pipeline for Neurological Diseases A new survey found 176 new medicines in development for neurologic diseases - up from 138 when the previous survey was conducted in 1999. More than 100 pharmaceutical and biotechnology companies are conducting this research, according to the Pharmaceutical Research and Manufacturers of America (PhRMA). "Pharmaceutical company researchers are using significant new knowledge about how the brain works to help patients with Alzheimer's, stroke, Parkinson's and other diseases," said PhRMA President Alan F. Holmer. The potential new medicines include: 16 for Parkinson's disease, which affects 1 out of every 100 Americans over age 60: P A R K I N S O N’ S D I S E A S E Product Name Company Indication Development Status Altropane™ Boston Life Sciences, Boston, MA imaging agent for early diagnosis of Parkinson’s disease Phase III completed (617) 425-0200 CEP-1347 Cephalon: West Chester, PA. Phase II (610) 344-0200 KW-6002 Kyowa Pharmaceutical; Princeton, NJ Phase II (609) 919-1100 Neotrofin leteprinim potassium (AIT-082) NeoTherapeutics Irvine, CA Phase II (949) 788-6700 NeuroCell™-PD (Orphan Drug) Diacrin Charlestown, MA; Genzyme General Cambridge, MA Phase II/III (617) 242-9100 neuroimmunophilin ligand (NIL-A) Guilford Pharmaceuticals Phase II completed Baltimore, MD (410) 631-6449 ReQuip ® ropinirole (controlled-release formulation) GlaxoSmithKline, Rsch. Triangle Park, NC;HCI Philadelphia, PA; SkyePharma San Diego, CA Phase II, (888) 825-5249 SLU308 Solvay Pharmaceuticals; Marietta, GA Phase II,(770) 578-5581 Spheramine™ human retinal pigment epithelial cells on microcarriers (Orphan Drug), Titan Pharmaceuticals; South San Francisco, CA Phase I/II (650) 244-4990 SPM 962 transdermal patch Schwarz Pharma Mequon, WI early and advanced Parkinson’s disease Phase II completed (800) 558-5114 SR 57667 Sanofi-Synthelabo, New York, NY (see also Alzheimer’s disease) Phase I (212) 551-4000 sumanirole (PNU 95666) Pharmacia;Peapack,NJ Phase II(888) 768-5501 Sygen ® Fidia Pharmaceutical Washington, DC (monosialogan-glioside GM1; see also spinal cord injury) Phase III (202) 371-9898 TV-1203 (etilevodopa) TEVA Pharmaceutical;North Wales, PA USA. Phase III (215) 591-3000 TVP-1012 (rasagiline)TEVA Pharmaceuticals; North Wales, PA, USA Phase III (215) 591-3000 Zelapar™ selegiline Amarin Pharmaceuticals; Warren, NJ in clinical trials (908) 580-5535 ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn